#liver decompensation

People who are living with all three viruses have a greater likelihood of progressing to end-stage liver disease.

Better results were observed even in people with increased portal hypertension.

People treated with direct-acting antivirals had a lower risk for liver failure and liver cancer as well as much lower mortality.

Less than 10% of people with cirrhosis were regularly monitored for liver cancer.

People with fatty liver disease and advanced fibrosis also had a greater incidence of diabetes.

However, some 10% experienced liver decompensation even after antiviral therapy.

After my liver transplant, being best friends with liver disease patients continues to be a huge part of my life.

This finding comes from data on COVID-19 cases diagnosed in people with chronic liver disease and reported to international registries.

Here are some tips to talk over with your doctor that could help you get into shape in no time at all.

A recent Swedish study defined a low-level detectable viral load as between 50 and 999.

Some experts have doubted the link between sustained virologic response and clinical outcomes.

People treated with Viread, Vemlidy or Baraclude are less likely to develop this malignancy.

This is the first major study to assess an eight-week regimen in people with all genotypes of hep C and compensated cirrhosis.

A large Canadian study found that just 2% of such women developed more severe cirrhosis within one year of delivery.

In the era of highly effective treatments for both viruses, HIV doesn’t speed the advancement of cirrhosis.

Conatus Pharmaceuticals’ study of emricasan for non-alcoholic steatohepatitis found the drug had no significant impact.